People · Operator
Named in public records as an officer, director or promoter · active 2009–2018 · Pharmaceuticals
| Company | Role | Sector | Stage | Raised · real | Value · est | Tied |
|---|---|---|---|---|---|---|
| Innovate Biopharmaceuticals, Inc. | — | Pharmaceuticals | Series C | $154.0M | $791.8M | 2018 |
| PhaseBio Pharmaceuticals Inc | — | Pharmaceuticals | Series C | $102.1M | $912.3M | 2009 |
| Innovate Biopharmaceuticals Inc. | — | Pharmaceuticals | Series B | $42.7M | $1.1B | 2018 |
Christopher Prior at the center, the companies they're named on, and every other operator named alongside them — an interlock map of shared founding teams, boards and funds. Name-matched, so treat as a research lead.
People named alongside Christopher Prior on the same companies — an interlock signal (shared founding team, board, or fund). Name-matched, so verify before acting.
| Operator | Shared | Their companies |
|---|---|---|
| Sandeep Laumas | 2 | 6 |
| Jay Madan | 2 | 2 |
| Clay Thorp | 1 | 10 |
| Justin Klein | 1 | 6 |
| Tyrell Rivers | 1 | 6 |
| Linda Tufts | 1 | 5 |
| Anthony Maida | 1 | 5 |
| Saira Ramasastry | 1 | 4 |
| Jonathan Mow | 1 | 3 |
| Asish K Xavier | 1 | 3 |
| Edward J. Sitar | 1 | 3 |
| Ashutosh Chilkoti | 1 | 2 |
| John Sharp | 1 | 2 |
| Douglas K Reed | 1 | 2 |
| Anna Kazanchyan | 1 | 2 |
| Thomas K Laundon | 1 | 2 |
| Joel Sussman | 1 | 2 |
| Michael K. Gutch | 1 | 2 |
| Craig K Rosen | 1 | 1 |
| Robert K Ingram | 1 | 1 |
People are matched by normalized name across records; a common name may merge distinct individuals. Treat as a research lead, the same way modeled valuations are directional, not quoted.